Search Within

Daniel C Danila

Formats
  1. Meeting Abstract (88)
  2. Journal Article (62)
  3. Book Section (1)
  4. Correspondence (1)
  5. Miscellaneous (1)
  6. Review (1)
Groups
  1. Department of Medicine (154)
  2. Genitourinary Oncology Service (154)
  3. Solid Tumor Oncology Division (154)
  4. GSK Faculty (50)
  5. Hematologic Malignancies, Division of (48)
  6. Epidemiology and Biostatistics (42)

More Groups

People
  1. Howard Scher (111)
  2. Michael Morris (53)
  3. Martin Fleisher (48)
  4. Dana Rathkopf (45)
  5. Susan Slovin (39)
  6. Aseem Anand (33)

More People

Years
  1. 2025 (2)
  2. 2024 (7)
  3. 2023 (9)
  4. 2022 (8)
  5. 2021 (12)
  6. 2020 (13)

More Years

Publications
  1. Journal of Clinical Oncology (73)
  2. Clinical Cancer Research (11)
  3. Annals of Oncology (10)
  4. Cancer Research (7)
  5. European Urology (5)
  6. JCO Precision Oncology (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (78)
  2. American Association for Cancer Research (20)
  3. Elsevier Science, Inc. (15)
  4. Oxford University Press (11)
  5. Elsevier Inc. (8)
  6. Society of Nuclear Medicine (3)

More Publishers

Results (154)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The analytic validation of prostate-specific mRNA detection in whole blood by RT-PCR as a prognostic biomarker for patients with castration- resistant prostate cancer (CRPC)
    Meeting Abstract

    Danila, D. C.; Anand, A.; Heller, G.; Wan, M.; Zehnder, M.; Khanin, R.; Schultz, N.; Fleisher, M.; Lilja, H.; Scher, H. I.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Shore, N.; Antonarakis, E. S.; Berry, W. R.; Alumkal, J. J.; Tutrone, R.; Saleh, M. N.; Redfern, C. H.; Hauke, R. J.; Liu, G.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Curley, T.; Rix, P. J.; Maneval, E. C.; Chen, I.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Predictive biomarkers in circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) through genomic analysis
    Meeting Abstract

    Danila, D. C.; Anand, A.; Yao, J.; Gierszewska, M.; Kramer, M.; Muller, S.; Fleisher, M.; McCombie, W. R.; Scher, H. I.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Predictive biomarkers in circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) through genomic analysis
    Meeting Abstract

    Danila, D. C.; Anand, A.; Yao, J.; Gierszewska, M.; Kramer, M.; Muller, S.; Fleisher, M.; McCombie, W. R.; Scher, H. I.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Rix, P. J.; Maneval, E. C.; Chen, I.; Fox, J. J.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A randomized phase 2 study of two doses of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Antonarakis, E. S.; Heath, E. I.; Smith, D. C.; Rathkopf, D.; Blackford, A. L.; Danila, D. C.; King, S.; Frost, A.; Ajiboye, A. S.; Zhao, M.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • A pilot study comparing the sensitivity of detecting prostate associated transcripts by adna test prostate assay to cell search in whole blood from patients with castration resistant prostate cancer
    Meeting Abstract

    Samoila, A.; Wan, M.; Anand, A.; Chuang, T.; Scher, H. I.; Fleisher, M.; Danila, D. C.
    Journal of Molecular Diagnostics (2012)

    Fulltext@MSK | Save
  • Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors
    Journal Article

    Mitsiades, N.; Sung, C. C.; Schultz, N.; Danila, D. C.; He, B.; Eedunuri, V. K.; Fleisher, M.; Sander, C.; Sawyers, C. L.; Scher, H. I.
    Cancer Research (2012)

    Fulltext@MSK | Save
  • The analytical validation of prostate specific mRNA detection in whole blood by reverse transcription-polymerase chain reaction (RT-PCR) as a prognostic biomarker for patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Danila, D.; Anand, A.; Heller, G.; Wan, M.; Zehnder, M.; Khanin, R.; Schultz, N.; Fleisher, M.; Lilja, H.; Scher, H. I.
    Annals of Oncology (2012)

    Fulltext@MSK | Save